Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL20817249 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL2719411 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL6155137 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10390115 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL308603 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL825430 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019924 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019927 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | claimed |
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | disclosed |
| CN-119970919-A | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating hypertension and heart failure and application of traditional Chinese medicine composition and traditional Chinese medicine preparation | 中国中医科学院广安门医院 | 2025-05-13 | — | — | CN | disclosed |
| US-20210393645-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2021-12-23 | — | — | US | disclosed |
| CN-107951835-B | Enalapril maleate preparation and application thereof | 湖南千金湘江药业股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-112225778-A | Preparation method of enalapril maleate | 辰欣药业股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20200338114-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC MEDICAL DEVICES INC. (CA) | 2020-10-29 | — | — | US | disclosed |
| US-20190262353-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2019-08-29 | — | — | US | disclosed |
| CN-109734775-A | A kind of refining methd of enalapril maleate | 辰欣药业股份有限公司 | 2019-05-10 | — | — | CN | disclosed |
| CN-107951835-A | A kind of enalapril maleate preparation and its application | 湖南千金湘江药业股份有限公司 | 2018-04-24 | — | — | CN | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1809303-A4 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC PHARMACEUTICALS INC (CA) | 2008-12-24 | — | — | EP | disclosed |
| US-20080063682-A1 | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans | ARC MEDICAL DEVICES, INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| EP-1809303-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC PHARMACEUTICALS, INC. (CA) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006032143-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS | ARC PHARMACEUTICALS, INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006032144-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING FUCANS FROM VARIOUS ECHINODERM SOURCES | ARC PHARMACEUTICALS, INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| EP-1631265-A2 | USE OF VARIOUS AGENTS FOR INHIBITING FIBROUS ADHESIONS | ARC PHARMACEUTICALS, INC. (CA) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004105737-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS USING VARIOUS AGENTS | ARC PHARMACEUTICALS, INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| US-6204393-B1 | IN AQUEOUS SOLUTION; CONTROLLING PH; NEUTRALIZATION | KANEKA CORPORATION (JP) | 2001-03-20 | — | — | US | disclosed |
| EP-1018516-A1 | METHOD FOR CRYSTALLIZING MALEIC ACID SALT OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL-L-PROLINE | KANEKA CORPORATION (JP) | 2000-07-12 | — | — | EP | disclosed |